The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Generic Makers See Softer Sales Growth in FY2013
May 16, 2014
- Merck Deal Marks a Stride towards Top 3 in Global Ophthalmic Space: Santen Veep
May 16, 2014
- Daiichi Sankyo Chair Shoda to Bow Out, Become Adviser
May 16, 2014
- Nichi-Iko to Assign over 70 Sales Reps Specializing in DPC Hospitals within 2014
May 16, 2014
- Otsuka Holdings’ Pharmaceutical Sales Top 1 Trillion Yen for First Time
May 15, 2014
- Hisamitsu Takes Aim at 190 Billion Yen Sales in FY2018
May 15, 2014
- Ono to Introduce Sales Reps Specializing in Oncology for Entry to Oncology Market in Japan
May 15, 2014
- Zeria Appoints New President for First Time in 32 Years
May 14, 2014
- Meiji Seika Pharma Pres. Matsuo to Helm Holding Firm
May 14, 2014
- Eisai Sales Up 4.7% Thanks to Humira, Halaven Growth
May 14, 2014
- Santen Acquires Merck’s Eye Drugs in Japan, Key Markets
May 14, 2014
- 4 Major Wholesalers’ Average Operating Margin Tops 1% Mark, Signaling Biz Recovery
May 13, 2014
- Astellas FY2013 Sales Up 16% on Rosy Revenues from Xtandi, Betanis
May 13, 2014
- March Ethical Drug Sales Zoom 13.8% on Pre-Tax Hike Demand: Crecon Report
May 13, 2014
- Astellas Pres. “Aware” of Rumored Marriage with Daiichi Sankyo, but Denies Any Merger at This Time
May 13, 2014
- Questionnaire Survey of Chronic Myeloid Leukemia Patients Finds 30 Unreported ADRs: Novartis
May 13, 2014
- Nippon Kayaku Predicts Remicade Biosimilar Sales of 1.1 Billion Yen for FY2014
May 13, 2014
- MTPC Plans to Reduce Costs by 10 Billion Yen by FY2016
May 12, 2014
- FY2013 Japan Ethical Drug Market Crosses 10 Trillion Yen Mark for 1st Time: IMS
May 12, 2014
- Shionogi Makes Record Operating, Ordinary Profits
May 12, 2014
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…